Might be a good time to return and post some of my thoughts......

Might be a good time to return and post some of my thoughts... About in line with what (IMO) was obvious 6 months ago.

• You can't sell product without additional expenses (TXMD)
• You can't quickly turn around diminishing sales for a product (TXMD)
• You can't rapidly increase sales and exposure for new products (Nextstellis)

There is danger in the MYX numbers -

• Women's division revenue is terrible!!!!!
• TXMD performance must have been terrible if "$61.9m was driven primarily by an increase in sales of NEXSTELLIS"
• IMO impairments are heading for a crash. Massive crash. BIG OUCHIES!

WTF:




How can we value TXMD at $363m ?!?!?!? Where are the sales!!!!! Where are the margins promised!!!!! These products have been in the books for 6 months and should have been tracking at ~$40m usd


Mayne overpaid again. Or - just have a terrible sales force that can't even maintain the momentum of existing products.

There numbers are devastating:



Unfortunately the promised recovery of Derm hasn't eventuated either These are terrible numbers and you'd have to question whether it is worth maintaining the products on the book. Revenue tanking. Contributing negative. If they can get some $$ - might be worth taking it.


All in all - VERY disappointing results as the sales of Woman's products are just not anywhere near where they need to be. There will have to be significant cost cutting to get into positive territory with the lack of growth.

But ......... The forward looking statement. If this is to be believed, there is a light - just need another 6 months to see if the sales can be accelerated.


Man I'm getting too old to be holding shares like Mayne DYOR and good luck.